People with type 1 diabetes have a high cardiovascular morbidity and mortality, particularly individuals with renal complications. This may be due to platelet hyperreactivity and/or diminished effect of aspirin treatment on platelet inhibition.
In this study, we will examine platelet aggregation and aspirin efficacy in persons with type 1 diabetes and different levels of albuminuria.
We will further include assessment of endothelial dysfunction, vascular inflammation and examination of the presence of atherosclerosis by determination of plaque volume in the carotid arteries by novel 3-dimensional ultrasound examination.
The results can give insights into the interplay between these factors.
The perspective will be to clarify the indication for aspirin treatment or need for alternative strategies, thereby potentially reducing the incidence of CVD in the future.
The study is a cross-sectional study including 300 participants with type 1 diabetes and 60 healthy control subjects. Participants will attend visits before and after seven days of aspirin treatment. Participants will be invited for a follow-up visit after two years and additional follow-up is planned after seven years.
The primary endpoint is to investigate platelet aggregation without aspirin treatment in participants with type 1 diabetes, stratified according to degree of albuminuria and compared to healthy control subjects.
Secondary we will investigate platelet aggregation after seven days of aspirin treatment, plaque volume, inflammation markers and endothelial dysfunction.
Professor, klinikchef Henrik Sillesen, Karkirurgisk Klinik, Rigshospitalet
Professor, overlæge Anne-Mette Hvas, Institut for Klinisk Medicin, Aarhus Universitetshospital Skejby